Systemic delivery of carbon monoxide by CORM-401 mitigates inflammation and alveolar bone loss in a rat model of periodontitis

BACKGROUND: Periodontitis is a chronic inflammatory disease characterized by excessive production of pro-inflammatory mediators, oxidative stress, and extracellular matrix degradation, ultimately leading to alveolar bone loss. Carbon monoxide (CO), an endogenous gasotransmitter produced during heme degradation, exhibits anti-inflammatory, antioxidant, and cytoprotective properties. CORM-401, an orally active CO-releasing molecule, can deliver CO systemically with high efficiency, and its ability to regulate energetic metabolism, reduce inflammation, and limit oxidative stress has been documented. However, its potential therapeutic effects in the treatment of periodontal disease have never been investigated. OBJECTIVE: To evaluate whether orally administered CORM-401 attenuates alveolar bone loss and gingival inflammation in a rat model of ligature-induced periodontitis. METHODS: Adult rats were subjected to ligature placement of the first molar to induce periodontitis and treated orally with CORM-401 or vehicle. Alveolar bone loss was quantified by CEJ-BC measurements. Gingival tissues were analyzed for cytokines (TNF-α and IL-1β), nitric oxide metabolites (NOx), and MMP-2 activity. Systemic inflammation was assessed by measuring plasma TNF-α. RESULTS: CORM-401 significantly reduced alveolar bone loss compared with vehicle-treated periodontitis rats. Treatment markedly decreased gingival levels of TNF-α and IL-1β. CORM-401 also reduced gingival NOx accumulation, indicating attenuation of oxidative and proteolytic stress. Plasma TNF-α was lower in CORM-401-treated animals, demonstrating a systemic anti-inflammatory effect. CONCLUSION: Oral administration of CORM-401 effectively mitigates periodontal inflammation and protects against alveolar bone loss in ligature-induced periodontitis. These findings suggest that CO-based pharmacological modulation may represent a promising host-directed therapeutic strategy for controlling periodontal tissue destruction.

Authors

Institutions

Publication Details

Journal
Cytokine
Published
2026-05-16
DOI
https://doi.org/10.1016/j.cyto.2026.157168
Primary Topic
Heme Oxygenase-1 and Carbon Monoxide
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Systemic delivery of carbon monoxide by CORM-401 mitigates inflammation and alveolar bone loss in a rat model of periodontitis

Luiz G.S. Branco, Roberta Foresti, Isabelly G. Solon, Roberto Motterlini et al.
Cytokine
Heme Oxygenase-1 and Carbon Monoxide
article

Systemic delivery of carbon monoxide by CORM-401 mitigates inflammation and alveolar bone loss in a rat model of periodontitis

Luiz G.S. Branco, Roberta Foresti, Isabelly G. Solon, Roberto Motterlini, Pedro H. Lopes, Maycon T. Emilio-Silva, Evelin C. Carnio, Wanderson S. Santos
article en

Abstract

BACKGROUND: Periodontitis is a chronic inflammatory disease characterized by excessive production of pro-inflammatory mediators, oxidative stress, and extracellular matrix degradation, ultimately leading to alveolar bone loss. Carbon monoxide (CO), an endogenous gasotransmitter produced during heme degradation, exhibits anti-inflammatory, antioxidant, and cytoprotective properties. CORM-401, an orally active CO-releasing molecule, can deliver CO systemically with high efficiency, and its ability to regulate energetic metabolism, reduce inflammation, and limit oxidative stress has been documented. However, its potential therapeutic effects in the treatment of periodontal disease have never been investigated. OBJECTIVE: To evaluate whether orally administered CORM-401 attenuates alveolar bone loss and gingival inflammation in a rat model of ligature-induced periodontitis. METHODS: Adult rats were subjected to ligature placement of the first molar to induce periodontitis and treated orally with CORM-401 or vehicle. Alveolar bone loss was quantified by CEJ-BC measurements. Gingival tissues were analyzed for cytokines (TNF-α and IL-1β), nitric oxide metabolites (NOx), and MMP-2 activity. Systemic inflammation was assessed by measuring plasma TNF-α. RESULTS: CORM-401 significantly reduced alveolar bone loss compared with vehicle-treated periodontitis rats. Treatment markedly decreased gingival levels of TNF-α and IL-1β. CORM-401 also reduced gingival NOx accumulation, indicating attenuation of oxidative and proteolytic stress. Plasma TNF-α was lower in CORM-401-treated animals, demonstrating a systemic anti-inflammatory effect. CONCLUSION: Oral administration of CORM-401 effectively mitigates periodontal inflammation and protects against alveolar bone loss in ligature-induced periodontitis. These findings suggest that CO-based pharmacological modulation may represent a promising host-directed therapeutic strategy for controlling periodontal tissue destruction.

CytokineVol. 204
Universidade de Ribeirão Preto (BR), Inserm (FR), Universidade de São Paulo (BR), Université Paris-Est Créteil (FR)
Fundação de Amparo à Pesquisa do Estado de São Paulo
Clean water and sanitation
Openalex Percentile: Top 7%
Heme Oxygenase-1 and Carbon Monoxide
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.